EUVIMEDEUVIMED entdecken
Crossref

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

Sibylle Loibl, Yeon Hee Park iD, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Jame Abraham, Aleix Prat, Naoki Niikura, Seock-Ah Im, Wei Li, Huiping Li, Yongsheng Wang und 19 weitere

New England Journal of Medicine · 26.02.2026 · 394 (9) · 845-857

DOI: 10.1056/nejmoa2514661 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 26.02.2026. Verfasst von Sibylle Loibl und 30 weiteren Autor:innen. Beteiligte Einrichtung: German Breast Group, Neu-Isenburg, Germany. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • German Breast Group, Neu-Isenburg, Germany.
  • Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Fudan University Cancer Hospital, Shanghai.
  • National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei.
  • Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.

ORCID-Profile: Yeon Hee Park

Zitieren

APA

Loibl, S., Park, Y. H., Shao, Z., Huang, C. S., Barrios, C., Abraham, J., Prat, A., Niikura, N., Im, S. A., Li, W., Li, H., Wang, Y., Yao, H., Kim, S. B., Geng, C. Z., Rodriguez Pantigoso, W., Ramírez Godinez, F. J., Song, C., Ching Chang, Y., …, & DESTINY-Breast05 Trial Investigators (2026). Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. New England Journal of Medicine, 394(9), 845-857. https://doi.org/10.1056/nejmoa2514661

Vancouver

Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. New England Journal of Medicine. 2026;394(9):845-857. doi:10.1056/nejmoa2514661

BibTeX
@article{Loibl2026,
  author = {Loibl, Sibylle and Park, Yeon Hee and Shao, Zhiming and Huang, Chiun-Sheng and Barrios, Carlos and Abraham, Jame and Prat, Aleix and Niikura, Naoki and Im, Seock-Ah and Li, Wei and Li, Huiping and Wang, Yongsheng and Yao, Herui and Kim, Sung-Bae and Geng, Cui-Zhi and Rodriguez Pantigoso, Wuilbert and Ramírez Godinez, Francisco Javier and Song, Chuangui and Ching Chang, Yuan and Antoniazzi, Augusto and Chen, Shin-Cheh and Li, Zhigao and Nowecki, Zbigniew and Lim, Joline and Mathias, Elton and Sato, Yuta and Lu, Wenjing and Abdel-Monem, Hanan and Untch, Michael and Geyer, Charles E and DESTINY-Breast05 Trial Investigators, DESTINY-Breast05 Trial Investigators},
  title = {Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {9},
  pages = {845--857},
  doi = {10.1056/nejmoa2514661}
}
Kostenlos starten →